Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
70
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The Strategy of Conditionally Replicating Adenovirus-Mediated PreS2 Mini-Antibody Expression Has Dual Effects of Inhibiting HBV Infection and Preventing Hepatocellular Carcinoma

Ziheng Ye1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
,
Su Zeng1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
,
Peipei Xu1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
,
Wenfei Liu1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
,
Shoufei Wang1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
,
Xiaotian Xia1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
,
Changqing Su2 Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgical Hospital and Institute, The Second Military Medical University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Minggao Guo1 Center of Thyroid and Parathyroid, Department of Thyroid, Parathyroid, Breast and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 1869-1876 | Published online: 24 Feb 2021

References

  • Zhang Q, Li ZQ, Liu H, Yang JH. Adenovirus-expressed preS2 antibody inhibits hepatitis B virus infection and hepatic carcinogenesis. World J Gastroenterol. 2012;18:349–355. doi:10.3748/wjg.v18.i4.34922294841
  • Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int. 2008;28:175–188. doi:10.1111/j.1478-3231.2007.01652.x18251977
  • Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1):S84–S101. doi:10.1016/j.jhep.2016.02.02127084040
  • Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 mutant-induced mammalian target of rapamycin signal pathways as potential therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma. Cell Transplant. 2017;26:429–438. doi:10.3727/096368916X69438228195035
  • Ochoa-Callejero L, Otano I, Vales A, et al. Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice. Vaccine. 2010;28:5323–5331. doi:10.1016/j.vaccine.2010.05.04320665977
  • Krawczyk A, Ludwig C, Jochum C, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 2014;32(39):5077–5082. doi:10.1016/j.vaccine.2014.06.07624975813
  • Guo M, Kang B, Zheng Q, et al. An anti-preS2 antibody protects human hepatocytes from hepatitis B virus infection. Acta Gastroenterol Belg. 2009;72:306–311.19902863
  • Sandhu HS, Roesel S, Sharifuzzaman M, Chunsuttiwat S, Tohme RA. Progress toward hepatitis B control - South-East Asia Region, 2016–2019. MMWR Morb Mortal Wkly Rep. 2020;69:988–992. doi:10.15585/mmwr.mm6930a232730237
  • Teufel A. Bioinformatics and database resources in hepatology. J Hepatol. 2015;62:712–719. doi:10.1016/j.jhep.2014.10.03625450718
  • Desplancq D, Rinaldi A-S, Stoessel A, et al. Single-chain Fv fragment antibodies selected from an intrabody library as effective mono- or bivalent reagents for in vitro protein detection. J Immunol Methods. 2011;369(1–2):42–50. doi:10.1016/j.jim.2011.04.00121501618
  • Krah S, Kolmar H, Becker S, Zielonka S. Engineering IgG-like bispecific antibodies-an overview. Antibodies. 2018;7:28. doi:10.3390/antib7030028
  • Zauli G, Corallini F, Zorzet S, Grill V, Marzari R, Secchiero P. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Invest New Drugs. 2012;30(1):405–407. doi:10.1007/s10637-010-9519-y20714918
  • Chang X, Cui H, Feng J, et al. Preparation of humanized ovarian carcinoma anti-idiotypic minibody. Hybrid Hybridomics. 2003;22(2):109–115. doi:10.1089/15368590332194803012831536
  • Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99–102. doi:10.1038/nature1035821886163
  • Chaurasiya S, Fong Y, Warner SG. Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges. Cancers. 2020;12(6):1699. doi:10.3390/cancers12061699
  • Li X, Su Y, Sun B, et al. An artificially designed interfering lncRNA expressed by oncolytic adenovirus competitively consumes OncomiRs to exert antitumor efficacy in hepatocellular carcinoma. Mol Cancer Ther. 2016;15(7):1436–1451. doi:10.1158/1535-7163.MCT-16-009627196772
  • Zhang Y, Fang L, Zhang Q, et al. An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma. Mol Oncol. 2013;7:346–358. doi:10.1016/j.molonc.2012.10.00723182495
  • Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13(1):84. doi:10.1186/s13045-020-00922-132600470
  • Ang L, Guo L, Wang J, Huang J, Lou X, Zhao M. Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer. Cancer Lett. 2020;479:42–53. doi:10.1016/j.canlet.2020.03.01232200038
  • Su C. Survivin in survival of hepatocellular carcinoma. Cancer Lett. 2016;379(2):184–190. doi:10.1016/j.canlet.2015.06.01626118774

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.